Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception
- 24 August 2011
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 25 (13) , 1647-1655
Abstract
Objectives: To describe antiretroviral therapy (ART) use and clinical status, at start of and during pregnancy, for HIV-positive women receiving ART at conception, including the proportion conceiving on drugs (efavirenz and didanosine) not recommended for use in early pregnancy. Methods: Women with a pregnancy resulting in a live-birth after 1995 (n = 1537) were identified in an observational cohort of patients receiving HIV care at 12 clinics in the UK by matching records with national pregnancy data. Treatment and clinical data were analysed for 375 women conceiving on ART, including logistic regression to identify factors associated with changing regimen during pregnancy. Results: Of the 375 women on ART, 39 (10%) conceived on dual therapy, 306 (82%) on triple therapy and 30 (8%) on more than three drugs. In total, 116 (31%) women conceived on a regimen containing efavirenz or didanosine (69 efavirenz, 54 didanosine, seven both). Overall, 38% (143) changed regimen during pregnancy, of whom 44% (n = 51) had a detectable viral load around that time. Detectable viral load was associated with increased risk of regimen change [adjusted odds ratio 2.97, 95% confidence interval (CI) (1.70–5.19)], while women on efavirenz at conception were three times more likely to switch than women on other drugs [3.40, (1.84–6.25)]. Regimen switching was also associated with year at conception [0.89, (0.83–0.96)]. Conclusion: These findings reinforce the need for careful consideration of ART use among women planning or likely to have a pregnancy in order to reduce viral load before pregnancy and avoid drugs not recommended for early antenatal use.Keywords
This publication has 25 references indexed in Scilit:
- Pregnancy Outcomes in Women Exposed to Efavirenz and Nevirapine: An Appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'IvoireJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USAHIV Medicine, 2010
- In Vitro Combination Studies of ANA598 with Anti-HCV Agents Demonstrate Enhanced Anti-viral ActivityAntiviral Research, 2010
- Impact of Antiretroviral Therapy on Incidence of Pregnancy among HIV-Infected Women in Sub-Saharan Africa: A Cohort StudyPLOS Medicine, 2010
- Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conceptionAntiviral Therapy, 2010
- Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort studyAIDS, 2008
- British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008HIV Medicine, 2008
- Adherence to Antiretrovirals Among US Women During and After PregnancyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationalityBJOG: An International Journal of Obstetrics & Gynaecology, 2007
- Periconceptional Exposure to Efavirenz and Neural Tube DefectsArchives of internal medicine (1960), 2002